Drug Trial Radar · NCT03161093
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,307
Actual
Start
Aug 17, 2017
Primary completion
Sep 9, 2019
Study completion Aug 27, 2021
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Teva Pharmaceutical Industries, Ltd.
- First posted
- May 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of fasinumab compared with placebo, when administered for up to 16 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: 1. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip 2. To evaluate the efficacy of fasinumab compared with placebo, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip 3. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip 4. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 52 weeks in patients with pain due to OA of the knee or hip 5. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 104 weeks in patients with pain due to OA of the knee or hip 6. To evaluate the pharmacokinetic (PK) profile of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks 7. To evaluate the PK profile of fasimumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks 8. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks 9. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks 10. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip
Conditions
- Osteoarthritis, Knee
- Osteoarthritis, Hip
Interventions
FasinumabDrug
Solution for injection in pre-filled syringe
NaproxenDrug
Pharmaceutical form: Capsule
Fasinumab-matching placeboDrug
Solution for injection in pre-filled syringe
Naproxen-matching placeboDrug
Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
- Change in the WOMAC Physical Function Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg Q4W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
- Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q8W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
- Change in the WOMAC Physical Function Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg Q8W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
Locations
139 sites in 12 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Research, PLLC
Mesa, Arizona
Arizona Research Center
Phoenix, Arizona
Tucson Orthopaedic Research Center
Tucson, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Medvin Clinical Research
Covina, California
TriWest Research Associates, LLC
El Cajon, California
BioSolutions Clinical Research
La Mesa, California
Pacific Arthritis Care Center
Los Angeles, California
Artemis Institute for Clinical Research
San Diego, California
Artemis Clinical Research
San Marcos, California
Lynn Institute of Denver
Aurora, Colorado
Lynn Institute of the Rockies
Colorado Springs, Colorado
Panorama Orthopedics & Spine Center
Golden, Colorado
Arthritis and Rheumatic Disease Specialties
Aventura, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Sensible Healthcare
Ocoee, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Jewett Orthopaedic Clinic
Orlando, Florida
Lovelace Scientific Resources
Venice, Florida
Meridian Clinical Research
Savannah, Georgia
Advanced Clinical Research
Meridian, Idaho
Medex Healthcare Research, Inc.
Chicago, Illinois
Northwestern University
Chicago, Illinois
Healthcare Research Network II, LLC
Flossmoor, Illinois
Integrated Clinical Trial Services, Inc.
West Des Moines, Iowa
Klein & Associates, MD PA
Cumberland, Maryland
Klein & Associates, MD, PA
Hagerstown, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland
Clinical Pharmacology Study Group
Worcester, Massachusetts
The Center for Pharmaceutical Research
Kansas City, Missouri
Medex Healthcare Research, Inc.
St Louis, Missouri
Sundance Clinical Research, LLC
St Louis, Missouri
Physician Research Collaboration, LLC
Lincoln, Nebraska
Lovelace Scientific Resources, Inc.
Albuquerque, New Mexico
United Medical Associates
Binghamton, New York
Regional Clinical Research, Inc.
Endwell, New York
Medex Healthcare Research
New York, New York
Buffalo Rheumatology and Medicine, PLLC
Orchard Park, New York
Orchard Park Family Practice
Orchard Park, New York
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.